| pubmed-article:17186240 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C0010868 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C1442989 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C0445223 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C1552599 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C1704787 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C1871955 | lld:lifeskim |
| pubmed-article:17186240 | lifeskim:mentions | umls-concept:C2000248 | lld:lifeskim |
| pubmed-article:17186240 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17186240 | pubmed:dateCreated | 2007-7-19 | lld:pubmed |
| pubmed-article:17186240 | pubmed:abstractText | SDX-101 is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac, and has anti-tumour activity in chronic lymphocytic leukaemia (CLL). SDX-308 and SDX-309 are more potent, structurally related indole-pyran analogues of SDX-101. The current study was performed to investigate and quantify the cytotoxic potentiating effects resulting from a combination of either SDX-101, SDX-308 or SDX-309 with standard cytotoxic agents used in the CLL treatment today. | lld:pubmed |
| pubmed-article:17186240 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17186240 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17186240 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17186240 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17186240 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17186240 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17186240 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17186240 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17186240 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17186240 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17186240 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17186240 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17186240 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:17186240 | pubmed:author | pubmed-author:QiChaoC | lld:pubmed |
| pubmed-article:17186240 | pubmed:author | pubmed-author:LarssonRolfR | lld:pubmed |
| pubmed-article:17186240 | pubmed:author | pubmed-author:AleskogAnnaA | lld:pubmed |
| pubmed-article:17186240 | pubmed:author | pubmed-author:LeoniLorenzoL | lld:pubmed |
| pubmed-article:17186240 | pubmed:author | pubmed-author:ElliottGaryG | lld:pubmed |
| pubmed-article:17186240 | pubmed:author | pubmed-author:LindhagenElin... | lld:pubmed |
| pubmed-article:17186240 | pubmed:author | pubmed-author:NissleSaraS | lld:pubmed |
| pubmed-article:17186240 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17186240 | pubmed:volume | 60 | lld:pubmed |
| pubmed-article:17186240 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17186240 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17186240 | pubmed:pagination | 545-53 | lld:pubmed |
| pubmed-article:17186240 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:meshHeading | pubmed-meshheading:17186240... | lld:pubmed |
| pubmed-article:17186240 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17186240 | pubmed:articleTitle | R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. | lld:pubmed |
| pubmed-article:17186240 | pubmed:affiliation | Division of Clinical Pharmacology, Uppsala University, Uppsala, Sweden. elin.lindhagen@medsci.uu.se | lld:pubmed |
| pubmed-article:17186240 | pubmed:publicationType | Journal Article | lld:pubmed |
